News will come out when the company has something to say. Work on the imaging is going forward, which is encouraging. I get the sense that Dr. Moro and Goshen were not anticipating it taking so long to cleave the antibodies, but as stated before, they've just recently crossed that bridge. A couple of other minor errors in the transcription to note (due to weariness last night)relate to reducing the chances of a "negative" reaction by injecting a patient with an antibody molecule. He called it an "immune reaction", not negative reaction. Also, the statement, "... we are going to now start the animal studies (testing, referring to mice) that they are going to need before they take this to the next level(which is imaging). (The next level he was referring to and stated was testing in humans, not imaging (my assumption,again, the accent. I began to understand after listening to the recorder a mulitude of times; this whole process is imaging) Sorry about that.
To answer your question, he seems to expect the price to increase above my average buy in, $1.19, at least by the end of the year. He stated that the $2.00 range is a much more reasonable price for this stock, and expressed surprise that we aren't @ or above the levels we reached after the Abbott anouncement! He is definitely upbeat!!! There also seems to be a lot of interest in the technology from other companies, and the meetings continue!
